ALTIUS is one of the largest Belgian independent law firms, consisting of approximately 65 lawyers. Established in Brussels, we advise Belgian and international companies on the legal aspects of transactions, projects and disputes.
We help our clients navigate through often-complex legislation and regulatory environments and provide clear solutions to a wide range of legal issues. In addition to our specialist legal knowledge, we focus on thinking creatively with our clients to offer tailor-made solutions. Our aim is to turn, through careful listening and awareness, strategic questions into clear, straightforward answers.
For tax-related issues, ALTIUS works closely with Tiberghien, a leading independent Belgian firm that specialises in tax law.
On 16 April 2020, a new Act was adopted by the Belgian parliament to increase the transparency of managed entry agreements (‘MEA’) concluded between pharmaceutical companies and the National Institute for Health and Disability Insurance (‘NIHDI’). MEAs stipulate confidential compensation mechanisms for the Belgian government regarding the publicly-listed price and reimbursement basis of the medicine(s) concerned. The Act provides that if the Belgian parliament’s Chamber of Representatives orders a management audit, then the Court of Audit is granted full access to…
On 8 April 2020, the Belgian federal agency for medicines and health products (‘FAMHP’) adopted a consolidated version of its decision (the ‘Decision’) taking the following urgent measures for certain listed medicines (and raw materials) to avoid medicine shortages during the SARS-CoV-2 pandemic: Wholesalers, full-line wholesalers and manufacturers are obliged to limit their sales to full-line wholesalers and pharmacies for the products concerned to amounts that correspond to the sales for the same period of the previous year increased by a…
With national governments scrambling to take measures in order to counter the Covid-19 pandemic, we are again confronted with the fact that a EU common policy in the healthcare field is quasi inexistent. This is equally so in respect of the pricing and reimbursement of medicines. While the so-called Transparency Directive 89/105/EEC provides for a limited harmonization of pricing & reimbursement procedures, one however cannot deny a growing tendency of national governments to look beyond their national borders and…